RT Journal Article
SR Electronic
T1 Analysis of Accumulated SARS-CoV-2 Seroconversion in North Carolina: The COVID-19 Community Research Partnership
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.03.11.21253226
DO 10.1101/2021.03.11.21253226
A1 Williamson, John C.
A1 Wierzba, Thomas F
A1 Santacatterina, Michele
A1 Munawar, Iqra
A1 Seals, Austin L
A1 Ballard, Christine Ann Pittman
A1 Alexander-Miller, Martha
A1 Runyon, Michael S
A1 McCurdy, Lewis H
A1 Gibbs, Michael A
A1 Ahmed, Amina
A1 Lagarde, William H
A1 Maguire, Patrick D
A1 King-Thiele, Robin
A1 Hamrick, Terri
A1 Ihmeidan, Abdalla
A1 Henderson, Shakira
A1 Uschner, Diane
A1 Herrington, David M
A1 Sanders, John W
YR 2021
UL http://medrxiv.org/content/early/2021/03/12/2021.03.11.21253226.abstract
AB Introduction The COVID-19 Community Research Partnership is a population-based longitudinal syndromic and sero-surveillance study. The study includes over 17,000 participants from six healthcare systems in North Carolina who submitted over 49,000 serology results. The purpose of this study is to use these serology data to estimate the cumulative proportion of the North Carolina population that has either been infected with SARS-CoV-2 or developed a measurable humoral response to vaccination.Methods Adult community residents were invited to participate in the study between April 2020 and February 2021. Demographic information was collected and daily symptom screen was completed using a secure, HIPPA-compliant, online portal. A portion of participants were mailed kits containing a lateral flow assay to be used in-home to test for presence of anti-SARS-CoV-2 IgM or IgG antibodies. The cumulative proportion of participants who tested positive at least once during the study was calculated. A standard Cox proportional hazards model was constructed to illustrate the probability of seroconversion over time up to December 20, 2020 (before vaccines available). A separate analysis was performed to describe the influence of vaccines during an extended period through February 15, 2021.Results 17,688 participants contributed at least one serology result. Approximately two-thirds of the population were female and almost three-quarters were between 30 and 64 years of age. The average number of serology test results submitted per participant was 3.0 (±1.9). At December 20, 2020, the overall probability of seropositivity in the CCRP population was 32.6%. At February 15, 2021 the probability among healthcare workers and non-healthcare workers was 83% and 49%, respectively. An inflection upward in the probability of seropositivity was demonstrated around the end of December, suggesting an influence of vaccinations, especially for healthcare workers. Among healthcare workers, those in the oldest age category (60+ years) were 38% less likely to have seroconverted by February 15, 2021.Conclusions Results of this study suggest more North Carolina residents may have been infected with SARS-CoV-2 than the number of documented cases as determined by positive RNA or antigen tests. The influence of vaccinations on seropositivity among North Carolina residents is also demonstrated. Additional research is needed to fully characterize the impact of seropositivity on immunity and the ultimate course of the pandemic.Competing Interest StatementThe authors have declared no competing interest.Clinical TrialNCT04342884Funding StatementFor the conduct of this study, institutions received funding from the CARES Act of the U.S. Department of Health and Human Services (HHS) through the state of North Carolina.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:IRB of Wake Forest Health Sciences provided approvalAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe data that support the findings of this study are available on request from the corresponding author [JCW]. The data are not publicly available due to the possibility that release could compromise research participant privacy/consent.